Skip to main content Accessibility help
×
Hostname: page-component-76fb5796d-25wd4 Total loading time: 0 Render date: 2024-04-26T10:34:15.563Z Has data issue: false hasContentIssue false

3 - Assessment and Diagnosis of Psychotic Symptoms in Older Adults

from Section 1 - Epidemiology, Historical Background, Illness Phenomenology, and Diagnostic Issues

Published online by Cambridge University Press:  15 March 2019

Carl I. Cohen
Affiliation:
SUNY Downstate Medical Center
Paul D. Meesters
Affiliation:
Friesland Mental Health Services
Get access

Summary

This chapter examines the types and prevalence of psychotic symptoms and disorders in older adults, and offers insight into distinguishing between the disorders and guidelines for treatment. Psychotic disorders are very common (lifetime prevalence 25%) with risk increasing with age. Prevalence rates have ranged from 1-13.4%. Psychotic disorders can be divided into “primary” (40%), due to the direct effect of a psychiatric disorder and “secondary” (60%), caused by a non-psychiatric condition. Dementia is the most common cause of psychoses. The mnemonic “6 Ds” can be used to remember the principal causes of psychotic disorders: Disease, Delirium, Drugs, Dementia, Depression and mania, and Delusions and schizophrenia spectrum disorders. There are no pathognomonic signs to differentiate psychosis caused by psychiatric illness from that caused by another condition, although there are some characteristics that may serve to distinguish them. There are few controlled treatment studies and most guidelines have been developed through expert consensus panels. It is recommended that psychosocial interventions should be tried initially and medication should be used only when the former has failed or when symptoms present a danger to the patient or caregiver.
Type
Chapter
Information
Schizophrenia and Psychoses in Later Life
New Perspectives on Treatment, Research, and Policy
, pp. 27 - 46
Publisher: Cambridge University Press
Print publication year: 2019

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Arciniegas, D.B., Psychosis. Continuum: Lifelong Learning in Neurology, 2015. 21(3 Behavioral Neurology and Neuropsychiatry): p. 715.Google ScholarPubMed
Holroyd, S. and Laurie, S., Correlates of psychotic symptoms among elderly outpatients. International Journal of Geriatric Psychiatry, 1999. 14(5): p. 379–84.3.0.CO;2-7>CrossRefGoogle ScholarPubMed
Karim, S. and Byrne, E.J., Treatment of psychosis in elderly people. Advances in Psychiatric Treatment, 2005. 11: p. 286–96.CrossRefGoogle Scholar
Sigström, R., Skoog, I., Sacuiu, S., et al., The prevalence of psychotic symptoms and paranoid ideation in non-demented population samples aged 70–82 years. International Journal of Geriatric Psychiatry, 2009. 24(12): p. 1413–19.CrossRefGoogle ScholarPubMed
Subramaniam, M., Abdin, E., Vaingankar, J., et al., Prevalence of psychotic symptoms among older adults in an Asian population. International Psychogeriatrics, 2016. 28(7): p. 1211–20.CrossRefGoogle Scholar
Soares, W.B., Ribeiz, S.R.I., Bassitt, D.P., De Oliveira, M.C., and Bottino, C.M.C., Psychotic symptoms in older people without dementia from a Brazilian community-based sample. International Journal of Geriatric Psychiatry, 2015. 30(5): p. 437–45.CrossRefGoogle ScholarPubMed
Cohen, C.I., Magai, C., Yaffee, R., and Walcott-Brown, L., Racial differences in paranoid ideation and psychoses in an older urban population. American Journal of Psychiatry, 2004. 161(5): p. 864–71.CrossRefGoogle Scholar
Manepalli, J.N., Gebretsadik, M., Hook, J., and Grossberg, G., Differential diagnosis of the older patient with psychotic symptoms. Primary Psychiatry, 2007. 14(8): p. 5562.Google Scholar
Webster, J. and Grossberg, G.T., Late-life onset of psychotic symptoms. American Journal of Geriatric Psychiatry, 1998. 6(3): p. 196202.CrossRefGoogle ScholarPubMed
Reinhardt, M.M. and Cohen, C.I., Late-life psychosis: diagnosis and treatment. Current Psychiatry Reports, 2015. 17(2): p. 1.CrossRefGoogle ScholarPubMed
American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders (DSM-5®). 2013, Arlington, VA: American Psychiatric Association.Google Scholar
Christenson, R. and Blazer, D., Epidemiology of persecutory ideation in an elderly population in the community. American Journal of Psychiatry, 1984. 141(9): p. 1088–91.Google Scholar
Östling, S., Bäckman, K., Waern, M., et al., Paranoid symptoms and hallucinations among the older people in Western Europe. International Journal of Geriatric Psychiatry, 2013. 28(6): p. 573–9.CrossRefGoogle ScholarPubMed
Ciompi, L., Catamnestic long-term study on the course of life and aging of schizophrenics. Schizophrenia Bulletin, 1980. 6(4): p. 606.CrossRefGoogle ScholarPubMed
American Psychiatric Association, The American Association of Psychiatry Practice Guideline on the Use of Antipsychotics to Treat Agitation or Psychosis in Patients with Dementia. 2016, Arlington, VA: American Psychiatric Association.Google Scholar
Inouye, S.K., Westendorp, R.G.J., and Saczynski, J.S., Delirium in elderly people. Lancet, 2014. 383(9920): p. 911–22.Google ScholarPubMed
Oh, E.S., Fong, T.G., Hshieh, T.T., et al., Delirium in older persons: advances in diagnosis and treatment. Journal of the American Medical Association, 2017. 318(12): p. 1161–74.Google ScholarPubMed
Inouye, S.K., van Dyck, C.H., Alessi, C.A., et al., Clarifying confusion: the confusion assessment method: a new method for detection of delirium. Annals of Internal Medicine, 1990. 113(12): p. 941–8.CrossRefGoogle Scholar
Boettger, S. and Breitbart, W., Phenomenology of the subtypes of delirium: phenomenological differences between hyperactive and hypoactive delirium. Palliative and Supportive Care, 2011. 9(2): p. 129–35.CrossRefGoogle ScholarPubMed
Meagher, D.J., Moran, M., Raju, B., et al., Phenomenology of delirium: assessment of 100 adult cases using standardised measures. British Journal of Psychiatry, 2007. 190: p. 135–41.CrossRefGoogle ScholarPubMed
Webster, R. and Holroyd, S., Prevalence of psychotic symptoms in delirium. Psychosomatics, 2000. 41(6): p. 519–22.CrossRefGoogle ScholarPubMed
Inouye, S.K., Kosar, C.M., Tommet, D., et al., The CAM-S: development and validation of a new scoring system for delirium severity in 2 cohorts. Annals of Internal Medicine, 2014. 160(8): p. 526–33.CrossRefGoogle ScholarPubMed
Bellelli, G., Morandi, A., Davis, D.H.J., et al., Validation of the 4AT, a new instrument for rapid delirium screening: a study in 234 hospitalised older people. Age and Ageing, 2014. 43(4): p. 496502.CrossRefGoogle ScholarPubMed
Marcantonio, E.R., Ngo, L.H., O'Connor, M., et al., 3D-CAM: derivation and validation of a 3-minute diagnostic interview for CAM-defined delirium: a cross-sectional diagnostic test study. Annals of Internal Medicine, 2014. 161(8): p. 554–61.CrossRefGoogle ScholarPubMed
Steis, M.R., Evans, L., Hirschman, K.B., et al., Screening for delirium using family caregivers: convergent validity of the Family Confusion Assessment Method and interviewer-rated confusion assessment method. Journal of the American Geriatrics Society, 2012. 60(11): p. 2121–6.CrossRefGoogle ScholarPubMed
Lipowski, Z., Delirium: Acute Confusional States. 1990, New York: Oxford University Press, p. 97.Google Scholar
Morandi, A., Di Santo, S.G., Cherubini, A., et al., Clinical features associated with delirium motor subtypes in older inpatients: results of a multicenter study. American Journal of Geriatric Psychiatry. 25(10): p. 1064–71.Google Scholar
Witlox, J., Eurelings, L.S.M., de Jonghe, J.F.M., et al., Delirium in elderly patients and the risk of postdischarge mortality, institutionalization, and dementia: a meta-analysis. Journal of the American Medical Association, 2010. 304(4): p. 443–51.Google ScholarPubMed
Siddiqi, N., Harrison, J.K., Clegg, A., et al., Interventions for preventing delirium in hospitalised non-ICU patients. Cochrane Database of Systematic Reviews, 2016: CD005563.Google ScholarPubMed
Ropacki, S.A. and Jeste, D.V., Epidemiology of and risk factors for psychosis of Alzheimer's disease: a review of 55 studies published from 1990 to 2003. American Journal of Psychiatry, 2005. 162(11): p. 2022–30.CrossRefGoogle ScholarPubMed
Scarmeas, N., Brandt, J., Albert, M., et al., Delusions and hallucinations are associated with worse outcome in Alzheimer disease. Archives of Neurology, 2005. 62(10): p. 1601–8.CrossRefGoogle ScholarPubMed
Murray, P.S., Kumar, S., Demichele-Sweet, M.A., and Sweet, R.A., Psychosis in Alzheimer's disease. Biological Psychiatry, 2014. 75(7): p. 542–52.CrossRefGoogle ScholarPubMed
Connors, M.H., Ames, D., Woodward, M., and Brodaty, H., Psychosis and clinical outcomes in Alzheimer disease: a longitudinal study. American Journal of Geriatric Psychiatry. 26(3): p. 304–13.Google Scholar
Kales, H.C., Gitlin, L.N., and Lyketsos, C.G., Assessment and management of behavioral and psychological symptoms of dementia. British Medical Journal, 2015. 350: p. h369.CrossRefGoogle ScholarPubMed
Brodaty, H. and Arasaratnam, C., Meta-analysis of nonpharmacological interventions for neuropsychiatric symptoms of dementia. American Journal of Psychiatry, 2012. 169(9): p. 946–53.CrossRefGoogle ScholarPubMed
Clare, L., Woods, R.T., Moniz Cook, E.D., Orrell, M., and Spector, A., Cognitive rehabilitation and cognitive training for early-stage Alzheimer's disease and vascular dementia. Cochrane Database of Systematic Reviews, 2003. (4): CD003260.Google ScholarPubMed
Forbes, D., Culum, I., Lischka, A.R., et al., Light therapy for managing cognitive, sleep, functional, behavioural, or psychiatric disturbances in dementia. Cochrane Database of Systematic Reviews, 2009(4): CD003946.Google ScholarPubMed
Thorgrimsen, L., Birks, T.P.H., Thorgrimsen, L.M., et al., Aroma therapy for dementia. Cochrane Database of Systematic Reviews, 2003(3): CD003150.Google ScholarPubMed
Rodda, J., Morgan, S., and Walker, Z., Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine. International Psychogeriatrics, 2009. 21(5): p. 813–24.CrossRefGoogle ScholarPubMed
Trinh, N.H., Hoblyn, J., Mohanty, S., and Yaffe, K., Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis. Journal of the American Medical Association, 2003. 289(2): p. 210–16.Google ScholarPubMed
Rolinski, M., Fox, C., Maidment, I., and McShane, R., Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease. Cochrane Database of Systematic Reviews, 2012(3): CD006504.Google ScholarPubMed
Cumbo, E. and Ligori, L.D., Differential effects of current specific treatments on behavioral and psychological symptoms in patients with Alzheimer's disease: a 12-month, randomized, open-label trial. Journal of Alzheimer's Disease, 2014. 39(3): p. 477–85.CrossRefGoogle ScholarPubMed
Gauthier, S., Loft, H., and Cummings, J., Improvement in behavioural symptoms in patients with moderate to severe Alzheimer's disease by memantine: a pooled data analysis. International Journal of Geriatric Psychiatry, 2008. 23(5): p. 537–45.CrossRefGoogle ScholarPubMed
Lachaine, J., Beauchemin, C., Crochard, A., and Bineau, S., The impact of memantine and cholinesterase inhibitor initiation for Alzheimer disease on the use of antipsychotic agents: analysis using the Regie de l'Assurance Maladie du Quebec Database. Canadian Journal of Psychiatry, 2013. 58(4): p. 195200.CrossRefGoogle ScholarPubMed
Gauthier, S., Wirth, Y., and Mobius, H.J., Effects of memantine on behavioural symptoms in Alzheimer's disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies. International Journal of Geriatric Psychiatry, 2005. 20(5): p. 459–64.CrossRefGoogle ScholarPubMed
Wilcock, G.K., Ballard, C.G., Cooper, J.A., and Loft, H., Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease: a pooled analysis of 3 studies. Journal of Clinical Psychiatry, 2008. 69(3): p. 341–8.Google ScholarPubMed
McShane, R., Areosa Sastre, A., and Minakaran, N., Memantine for dementia. Cochrane Database of Systematic Reviews, 2006(2): CD003154.Google ScholarPubMed
Jeste, D.V., Blazer, D., Casey, D., et al., ACNP White Paper: update on use of antipsychotic drugs in elderly persons with dementia. Neuropsychopharmacology, 2008. 33(5): p. 957–70.CrossRefGoogle ScholarPubMed
Schneider, L.S., Dagerman, K., and Insel, P.S., Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. American Journal of Geriatric Psychiatry, 2006. 14(3): p. 191210.CrossRefGoogle ScholarPubMed
Schneider, L.S., Dagerman, K.S., and Insel, P., Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. Journal of the American Medical Association, 2005. 294(15): p. 1934–43.Google ScholarPubMed
Jeste, D.V., Barak, Y., Madhusoodanan, S., Grossman, F., and Gharabawi, G., International multisite double-blind trial of the atypical antipsychotics risperidone and olanzapine in 175 elderly patients with chronic schizophrenia. American Journal of Geriatric Psychiatry, 2003. 11(6): p. 638–47.CrossRefGoogle ScholarPubMed
Cummings, J., Isaacson, S., Mills, R., et al., Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet, 2014. 383(9916): p. 533–40.CrossRefGoogle ScholarPubMed
Fox, S.H., Pimavanserin as treatment for Parkinson's disease psychosis. Lancet, 2014. 383(9916): p. 494–6.CrossRefGoogle ScholarPubMed
Maher, A.R., Maglione, M., Bagley, S., et al., Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis. Journal of the American Medical Association, 2011. 306(12): p. 1359–69.Google ScholarPubMed
Meeks, T.W. and Jeste, D.V., Beyond the black box: what is the role for antipsychotics in dementia? Current Psychiatry, 2008. 7(6): p. 5065.Google ScholarPubMed
Seitz, D.P., Adunuri, N., Gill, S.S., et al., Antidepressants for agitation and psychosis in dementia. Cochrane Database of Systematic Reviews, 2011(2): CD008191.Google ScholarPubMed
Finkel, S.I., Mintzer, J.E., Dysken, M., et al., A randomized, placebo-controlled study of the efficacy and safety of sertraline in the treatment of the behavioral manifestations of Alzheimer's disease in outpatients treated with donepezil. International Journal of Geriatric Psychiatry, 2004. 19(1): p. 918.CrossRefGoogle ScholarPubMed
Pollock, B.G., Mulsant, B.H., Rosen, J., et al., A double-blind comparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia. American Journal of Geriatric Psychiatry, 2007. 15(11): p. 942–52.CrossRefGoogle ScholarPubMed
Porsteinsson, A.P., Drye, L.T., Pollock, B.G., et al., Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. Journal of the American Medical Association, 2014. 311(7): p. 682–91.Google ScholarPubMed
Alexopoulos, G.S., Streim, J.E., and Carpenter, D., Commentary: expert consensus guidelines for using antipsychotic agents in older patients. The Journal of Clinical Psychiatry, 2004. 65(suppl 2): p. 100–2.Google Scholar
American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders (DSM-5®). 2013, Arlington, VA: American Psychiatric Association.Google Scholar
Brunelle, S., Cole, M.G., and Elie, M., Risk factors for the late-onset psychoses: a systematic review of cohort studies. International Journal of Geriatric Psychiatry, 2012. 27(3): p. 240–52.CrossRefGoogle ScholarPubMed
Howard, R., Rabins, P.V., Seeman, M.V., and Jeste, D.V., Late-onset schizophrenia and very-late-onset schizophrenia-like psychosis: An international consensus. American Journal of Psychiatry, 2000. 157(2): p. 172–8.CrossRefGoogle ScholarPubMed
Stafford, J., Howard, R., and Kirkbride, J.B., The incidence of very late-onset psychotic disorders: a systematic review and meta-analysis, 1960-2016. Psychological Medicine, 2017: p. 12.Google ScholarPubMed
Cohen, C.I., Meesters, P.D., and Zhao, J., New perspectives on schizophrenia into later life: Implications for treatment, policy, and research. Lancet Psychiatry, 2015. 2(4): p. 340–50.CrossRefGoogle ScholarPubMed
Palmer, B.W., McClure, F.S., and Jeste, D.V., Schizophrenia in late life: findings challenge traditional concepts. Harvard Review of Psychiatry, 2001. 9(2): p. 51–8.CrossRefGoogle ScholarPubMed
Vahia, I.V., Palmer, B.W., Depp, C., et al., Is late‐onset schizophrenia a subtype of schizophrenia? Acta Psychiatrica Scandinavica, 2010. 122(5): p. 414–26.CrossRefGoogle ScholarPubMed
Iglewicz, A., Meeks, T.W., and Jeste, D.V., New wine in old bottle: late-life psychosis. Psychiatric Clinics of North America, 2011. 34(2): p. 295318.CrossRefGoogle ScholarPubMed
Howard, R., Almeida, O., and Levy, R., Phenomenology, demography and diagnosis in late paraphrenia. Psychological Medicine, 1994. 24(02): p. 397410.CrossRefGoogle ScholarPubMed
Essali, A. and Ali, G., Antipsychotic drug treatment for elderly people with late-onset schizophrenia. Cochrane Database of Systematic Reviews, 2012. (2): CD004162.Google ScholarPubMed
Marriott, R.G., Neil, W., and Waddingham, S., Antipsychotic medication for elderly people with schizophrenia. Cochrane Database of Systematic Reviews, 2006(1): CD005580.Google ScholarPubMed
Suzuki, T., Remington, G., Uchida, H., et al., Management of schizophrenia in late life with antipsychotic medications: a qualitative review. Drugs and Aging, 2011. 28(12): p. 961–80.CrossRefGoogle ScholarPubMed
Tzimos, A., Samokhvalov, V., Kramer, M., et al., Safety and tolerability of oral paliperidone extended-release tablets in elderly patients with schizophrenia: a double-blind, placebo-controlled study with six-month open-label extension. American Journal of Geriatric Psychiatry, 2008. 16(1): p. 3143.CrossRefGoogle ScholarPubMed
Graff-Guerrero, A., Rajji, T.K., Mulsant, B.H., et al., Evaluation of antipsychotic dose reduction in late-life schizophrenia: a prospective dopamine D2/3 receptor occupancy study. JAMA Psychiatry, 2015. 72(9): p. 927–34.CrossRefGoogle ScholarPubMed
Granholm, E., McQuaid, J.R., McClure, F.S., et al., A randomized, controlled trial of cognitive behavioral social skills training for middle-aged and older outpatients with chronic schizophrenia. American Journal of Psychiatry, 2005. 162(3): p. 520–9.CrossRefGoogle ScholarPubMed
Granholm, E., McQuaid, J.R., McClure, F.S., et al., Randomized controlled trial of cognitive behavioral social skills training for older people with schizophrenia: 12-month follow-up. Journal of Clinical Psychiatry, 2007. 68(5): p. 730–7.Google Scholar
Patterson, T.L., Bucardo, J., McKibbin, C.L., et al., Development and pilot testing of a new psychosocial intervention for older Latinos with chronic psychosis. Schizophrenia Bulletin, 2005. 31(4): p. 922–30.CrossRefGoogle ScholarPubMed
Patterson, T.L., Mausbach, B.T., McKibbin, C., et al., Functional Adaptation Skills Training (FAST): A randomized trial of a psychosocial intervention for middle-aged and older patients with chronic psychotic disorders. Schizophrenia Research, 2006. 86(1-3): p. 291–9.CrossRefGoogle Scholar
Bartels, S.J., Pratt, S.I., Mueser, K.T., et al., Long-term outcomes of a randomized trial of integrated skills training and preventive healthcare for older adults with serious mental illness. American Journal of Geriatric Psychiatry, 2014. 22(11): p. 1251–61.CrossRefGoogle ScholarPubMed
Mueser, K.T., Pratt, S.I., Bartels, S.J., et al., Randomized trial of social rehabilitation and integrated health care for older people with severe mental illness. Journal of Consulting and Clinical Psychology, 2010. 78(4): p. 561–73.CrossRefGoogle ScholarPubMed
Meesters, P.D., Haan, L., Comijs, H.C., et al., Schizophrenia spectrum disorders in later life: prevalence and distribution of age at onset and sex in a Dutch catchment area. American Journal of Geriatric Psychiatry, 2012. 20(1): p. 1828.CrossRefGoogle Scholar
Post, F., Schizo-affective symptomatology in late life. British Journal of Psychiatry, 1971. 118(545): p. 437–45.CrossRefGoogle ScholarPubMed
Baran, X.Y. and Young, R.C., Bipolar and depressive types of schizoaffective disorder in old age. American Journal of Geriatric Psychiatry, 2006. 14(4): p. 382–3.CrossRefGoogle ScholarPubMed
Kendler, K.S., Demography of paranoid psychosis (delusional disorder): a review and comparison with schizophrenia and affective illness. Archives of General Psychiatry, 1982. 39(8): p. 890902.CrossRefGoogle ScholarPubMed
Maher, B., Delusional thinking and cognitive disorder. Integrative Physiological and Behavioral Science, 2005. 40(3): p. 136–46.CrossRefGoogle ScholarPubMed
Maglione, J.E., Vahia, I.V., and Jeste, D.V., Schizophrenia spectrum and other psychotic disorders. In The American Psychiatric Publishing Textbook of Geriatric Psychiatry, ed. Steffens, D.C., Blazer, D.G., and Thakur, M.E., 2015.Google Scholar
Mews, M.R. and Quante, A., Comparative efficacy and acceptability of existing pharmacotherapies for delusional disorder: a retrospective case series and review of the literature. Journal of Clinical Psychopharmacology, 2013. 33(4): p. 512–19.CrossRefGoogle ScholarPubMed
Byers, A.L., Yaffe, K., Covinsky, K.E., et al., High occurrence of mood and anxiety disorders among older adults: The National Comorbidity Survey Replication. Archives of General Psychiatry, 2010. 67(5): p. 489–96.CrossRefGoogle ScholarPubMed
Luppa, M., Sikorski, C., Luck, T., et al., Age- and gender-specific prevalence of depression in latest-life: systematic review and meta-analysis. Journal of Affective Disorders, 2012. 136(3): p. 212–21.CrossRefGoogle ScholarPubMed
Kessler, R.C., Berglund, P., Demler, O., et al., Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the national comorbidity survey replication. Archives of General Psychiatry, 2005. 62(6): p. 593602.CrossRefGoogle ScholarPubMed
Brodaty, H., Luscombe, G., Parker, G., et al., Increased rate of psychosis and psychomotor change in depression with age. Psychological Medicine, 1997. 27(5): p. 1205–13.CrossRefGoogle ScholarPubMed
Bingham, K.S., Whyte, E.M., Meyers, B.S., et al., Relationship between cerebrovascular risk, cognition, and treatment outcome in late-life psychotic depression. American Journal of Geriatric Psychiatry, 2015. 23(12): p. 1270–5.CrossRefGoogle ScholarPubMed
Nelson, E.B., Psychotic depression: beyond the antidepressant/antipsychotic combination. Current Psychiatry Reports, 2012. 14(6): p. 619–23.CrossRefGoogle ScholarPubMed
Andreescu, C., Mulsant, B.H., Rothschild, A.J., et al., Pharmacotherapy of major depression with psychotic features: what is the evidence? Psychiatric Annals, 2006. 36(1): p. 31–8.Google Scholar
Geduldig, E.T. and Kellner, C.H., Electroconvulsive therapy in the elderly: new findings in geriatric depression. Current Psychiatry Reports, 2016. 18(4): p. 40.CrossRefGoogle ScholarPubMed
Wijkstra, J., Lijmer, J., Burger, H., et al., Pharmacological treatment for psychotic depression. Cochrane Database of Systematic Reviews, 2015(7): p. CD004044.Google ScholarPubMed
Leadholm, A.K., Rothschild, A.J., Nolen, W.A., et al., The treatment of psychotic depression: is there consensus among guidelines and psychiatrists? Journal of Affective Disorders, 2013. 145(2): p. 214–20.CrossRefGoogle ScholarPubMed
Meyers, B.S., Flint, A.J., Rothschild, A.J., et al., A double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression. Archives of General Psychiatry, 2009. 66(8): p. 838–47.CrossRefGoogle ScholarPubMed
Rothschild, A.J., Williamson, D.J., Tohen, M.F., et al., A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. Journal of Clinical Psychopharmacology, 2004. 24(4): p. 365–73.CrossRefGoogle ScholarPubMed
Young, R.C., Mulsant, B.H., Sajatovic, M., et al., GERI-BD: a randomized double-blind controlled trial of lithium and divalproex in the treatment of mania in older patients with bipolar disorder. American Journal of Psychiatry, 2017. 174(11): p. 1086–93.CrossRefGoogle ScholarPubMed
Rej, S., Yu, C., Shulman, K., et al., Medical comorbidity, acute medical care use in late-life bipolar disorder: a comparison of lithium, valproate, and other pharmacotherapies. General Hospital Psychiatry, 2015. 37(6): p. 528–32.CrossRefGoogle ScholarPubMed
Sajatovic, M. and Chen, P., Geriatric bipolar disorder. Psychiatric Clinics of North America, 2011. 34(2): p. 319–33.CrossRefGoogle ScholarPubMed
Sajatovic, M., Calabrese, J.R., and Mullen, J., Quetiapine for the treatment of bipolar mania in older adults. Bipolar Disorder, 2008. 10(6): p. 662–71.CrossRefGoogle ScholarPubMed
Sajatovic, M., Dines, P., Fuentes-Casiano, E., et al., Asenapine in the treatment of older adults with bipolar disorder. International Journal of Geriatric Psychiatry, 2015. 30(7): p. 710–19.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×